Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | GUCY1A1 | Q02108 | 18/20 | 0.41 |
| ▸ | GUCY1B1 | Q02153 | 18/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9980387 | 0.86 | PDE5A (0.46) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL15117031 | 0.81 | PDE5A (0.44) | PDE5AGUCY1A1GUCY1B1KMO | |
| SCHEMBL21413147 | 0.76 | KDM4C (0.41) | PDE5AGUCY1A1GUCY1B1KMO | |
| SCHEMBL18999258 | 0.74 | KMO (0.42) | PDE5AGUCY1A1GUCY1B1KMO | |
| SCHEMBL20161332 | 0.74 | GUCY1A1 (0.39) | GUCY1A1GUCY1B1 | |
| SCHEMBL14776630 | 0.74 | PDE5A (0.49) | PDE5AGUCY1A1GUCY1B1KMO | |
| SCHEMBL20161258 | 0.68 | PDE5A (0.52) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL14776861 | 0.65 | GUCY1A1 (0.34) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL15541683 | 0.63 | KMO (0.51) | KMO | |
| SCHEMBL29781920 | 0.63 | KMO (0.51) | KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | PDE5A 12/4885GUCY1A1 4/4885GUCY1B1 6/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | PDE5A 12/4885GUCY1A1 4/4885GUCY1B1 6/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | PDE5A 12/4885GUCY1A1 4/4885GUCY1B1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.